jRCT1030200192进行中（未招募）不适用
Translational research for a Phase I study of tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
Chugai pharma0 个研究点目标入组 10 人开始时间: 2019年5月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
- 主要终点
- Suppresion of IL-6 signaling
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Partipants for a Phase I study of tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
- •Tumor tissue from the patient was available
- •Written informed consent for participation in the study is obtained at the discretion of the patient.
排除标准
- 未提供
结局指标
主要结局
Suppresion of IL-6 signaling
using a decrease of intratumoral pSTAT3 expression
Suppresion of desmoplasia
using a decrease of intratumoral alppha-SMA expression
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid TumorsCTIS2022-500849-24-00Tolremo Therapeutics AG25
招募中
不适用
TRIC (TRIC)jRCTs04124015130
进行中（未招募）
不适用
TCD-12261jRCT2042230075Terumo Corporation40
进行中（未招募）
不适用
Administration of a single dose or of three doses of AM-101to patients with Tinnitus (Ringing in the Ears) and comparision of both doses.Acute inner ear tinnitus following acute acustic trauma, acute otitis media, middle ear surgery, or inner ear barotraumaMedDRA version: 14.1Level: PTClassification code 10043882Term: TinnitusSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2011-005384-24-DEAuris Medical AG72
进行中（未招募）
1 期
Administration of a single dose or of three doses of AM-101to patients with Tinnitus (Ringing in the Ears) and comparision of both doses.EUCTR2011-005384-24-BEAuris Medical AG72